Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Agenus Inc. < Previous 1 2 Next > Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 September 13, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 September 09, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Participate in September Investor Conferences September 03, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports Second Quarter 2024 Operational and Financial Results August 08, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Appointment of Tom Harrison to Board of Directors August 08, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Publishes Seminal Study on Botensilimab’s Activity in Treatment-Resistant Cancers August 07, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update July 26, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces End-of-Phase-2 Meeting Outcomes and Topline Interim Phase 2 Data for BOT/BAL in MSS Colorectal Cancer July 18, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Significant Tumor Reductions in Neoadjuvant MSS Colon Cancer Patients Treated with Botensilimab/Balstilimab Presented at ESMO GI Conference June 28, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies June 27, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors June 17, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Virtual Annual Shareholders Meeting June 04, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 24, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Breakthrough Data on Botensilimab/Balstilimab in MSS CRC Presented at the 2024 ASCO Annual Meeting May 23, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference May 23, 2024 From Agenus Inc. Via Business Wire Tickers AGEN FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/BAL Therapy for Relapsed or Refractory Metastatic Colorectal Cancer May 16, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports First Quarter 2024 Results May 07, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Regains Compliance with Nasdaq Minimum Bid Price Requirement May 01, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Botensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual Meeting April 24, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Provide First Quarter 2024 Financial Report and Corporate Update April 23, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal Cancer April 12, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Reverse Stock Split of Common Stock April 05, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports Fourth Quarter and Full Year 2023 Results March 14, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024 March 06, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 05, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report February 29, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Participate in Leerink Partners Global Biopharma Conference February 26, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference January 31, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Botensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer Population January 22, 2024 From Agenus Inc. Via Business Wire Tickers AGEN Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Agenus Inc. Via Business Wire Tickers AGEN < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.